NO975334D0 - Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst - Google Patents

Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst

Info

Publication number
NO975334D0
NO975334D0 NO975334A NO975334A NO975334D0 NO 975334 D0 NO975334 D0 NO 975334D0 NO 975334 A NO975334 A NO 975334A NO 975334 A NO975334 A NO 975334A NO 975334 D0 NO975334 D0 NO 975334D0
Authority
NO
Norway
Prior art keywords
silicristin
silidianin
mixtures
effective amount
therapeutically effective
Prior art date
Application number
NO975334A
Other languages
English (en)
Other versions
NO317153B1 (no
NO975334L (no
Inventor
Ezio Bombardelli
Paolo Morazzoni
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of NO975334D0 publication Critical patent/NO975334D0/no
Publication of NO975334L publication Critical patent/NO975334L/no
Publication of NO317153B1 publication Critical patent/NO317153B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19975334A 1995-05-23 1997-11-20 Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst NO317153B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI951047A IT1274549B (it) 1995-05-23 1995-05-23 Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
PCT/EP1995/003993 WO1996037209A1 (en) 1995-05-23 1995-10-10 Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast

Publications (3)

Publication Number Publication Date
NO975334D0 true NO975334D0 (no) 1997-11-20
NO975334L NO975334L (no) 1997-11-20
NO317153B1 NO317153B1 (no) 2004-08-30

Family

ID=11371650

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975334A NO317153B1 (no) 1995-05-23 1997-11-20 Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst

Country Status (20)

Country Link
US (2) US5912265A (no)
EP (1) EP0828500B1 (no)
JP (1) JP3178844B2 (no)
KR (1) KR100290030B1 (no)
CN (1) CN1148181C (no)
AT (1) ATE268183T1 (no)
AU (1) AU709802B2 (no)
CA (1) CA2221753C (no)
DE (1) DE69533112T2 (no)
DK (1) DK0828500T3 (no)
ES (1) ES2222466T3 (no)
FI (1) FI119100B (no)
HU (1) HU220627B1 (no)
IT (1) IT1274549B (no)
NO (1) NO317153B1 (no)
PL (1) PL182064B1 (no)
PT (1) PT828500E (no)
RU (1) RU2161488C2 (no)
SI (1) SI0828500T1 (no)
WO (1) WO1996037209A1 (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432560A1 (fr) 1978-08-02 1980-02-29 Texas Instruments Inc Procede de decapage de metaux, en particulier d'aluminium, au plasma de tetrachlorure de silicium
US6379714B1 (en) 1995-04-14 2002-04-30 Pharmaprint, Inc. Pharmaceutical grade botanical drugs
RU2188819C2 (ru) * 1996-08-12 2002-09-10 Селджин Корпорейшн НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
WO2000066232A2 (fr) 1999-04-30 2000-11-09 Salomon S.A. Chassis articule
FR2792846B1 (fr) 1999-04-30 2001-07-27 Salomon Sa Patin a roues en ligne du type a platine superieure articulee
KR100342942B1 (ko) * 1999-07-05 2002-07-02 민경윤 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
WO2002083124A1 (en) * 2000-10-06 2002-10-24 Probiochem, Llc A composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
WO2002067853A2 (en) * 2000-10-06 2002-09-06 Probiochem, Llc A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
AU2002253795B2 (en) * 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
US20040092565A1 (en) * 2001-07-25 2004-05-13 George Kindness Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
EP1314438A1 (en) * 2001-11-23 2003-05-28 Nutricia N.V. Anti-proliferative composition
JP2006510606A (ja) * 2002-10-15 2006-03-30 セルジーン・コーポレーション 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
AU2003287381B2 (en) * 2002-10-31 2008-03-06 Celgene Corporation Composition for the treatment of macular degenration
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
NZ540384A (en) * 2002-11-06 2008-06-30 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
WO2004054501A2 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
JP2006510617A (ja) * 2002-11-18 2006-03-30 セルジーン・コーポレーション （＋）−３−（３，４−ジメトキシ−フェニル）−３−（１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−プロピオンアミドの使用方法およびそれを含む組成物
CN100402023C (zh) * 2003-06-21 2008-07-16 山东绿叶天然药物研究开发有限公司 一种水飞蓟素软胶囊及其制备方法
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
KR100577514B1 (ko) * 2003-10-21 2006-05-10 한미약품 주식회사 비페닐디메틸디카복실레이트, 및 카르두스 마리아누스추출물 또는 이로부터 정제된 실리빈을 함유하는 경구용마이크로에멀젼 조성물
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
MXPA06008520A (es) * 2004-01-28 2008-02-13 Androscience Corp Realce de la actividad anti-androgenica por una combinacion de los inhibidores que apuntan diversos pasos de un camino esteroide-dependiente de la activacion del gen y su aplicacion.
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
EP1744748A4 (en) * 2004-04-14 2009-08-12 Celgene Corp METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
US20050239867A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
RU2283658C1 (ru) * 2005-03-29 2006-09-20 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Средство и способ лечения и профилактики онкологических заболеваний
RU2292898C1 (ru) * 2005-08-02 2007-02-10 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Противоопухолевый липосомный препарат направленного действия
KR20080042158A (ko) 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
RU2306945C1 (ru) * 2006-02-15 2007-09-27 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Профилактическая композиция на основе веществ фенольной природы и фосфолипидов
RU2310453C1 (ru) * 2006-02-28 2007-11-20 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Способ получения гидрофильного комплекса на основе флавонолигнанов и фосфолипидов
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
DK2428513T3 (en) 2006-09-26 2017-08-21 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
JP2010515685A (ja) 2007-01-08 2010-05-13 アンドロサイエンス コーポレーション （置換フェニル）−プロペナール部分を伴う化合物、その誘導体、生物学的活性およびその使用
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US7907654B2 (en) * 2007-04-27 2011-03-15 Hewlett-Packard Development Company, L.P. Laser diode with a grating layer
CN101820765A (zh) 2007-07-31 2010-09-01 安德鲁科技有限公司 包含雄激素受体降解(ard)增强剂的组合物和预防性或治疗性治疗皮肤病与脱发的方法
AU2008305581C1 (en) 2007-09-26 2014-12-11 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
CZ300846B6 (cs) * 2008-06-26 2009-08-26 Agra Group, A. S. Vodorozpustný prípravek na bázi flavanonol lignanu a zpusob jeho prípravy
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PE20110547A1 (es) 2008-10-29 2011-08-04 Celgene Corp Compuestos de isoindolina con actividad anticancerigena
RU2379046C1 (ru) * 2008-11-18 2010-01-20 Сергей Викторович Луценко Композиция для терапии патологий печени и онкологических заболеваний
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US8716252B2 (en) 2009-12-22 2014-05-06 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their pharmaceutical uses
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
MX347928B (es) 2011-01-10 2017-05-19 Celgene Corp Derivados de fenetilsulfona isoindolina y su uso.
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
JP5959543B2 (ja) 2011-03-11 2016-08-02 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
WO2013040120A1 (en) 2011-09-14 2013-03-21 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
RS60415B1 (sr) 2011-12-27 2020-07-31 Amgen (Europe) GmbH Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
DK2882737T3 (da) 2012-08-09 2019-05-13 Celgene Corp Fast form af (s)-3-(4-((4-morpholinmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorid
EP2752201A1 (en) * 2013-01-04 2014-07-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. C-terminal HSP90 inhibitors to treat pituitary adenomas
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
CN104714708B (zh) * 2013-12-11 2018-12-14 新益先创科技股份有限公司 控制点感测面板及其设计方法
TW201540323A (zh) 2014-01-15 2015-11-01 Celgene Corp ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
US20170172921A1 (en) * 2016-12-14 2017-06-22 Mahmoud Reza Jaafari Polyphenolic compounds encapsualated in long circulating liposomes and use thereof
WO2019233440A1 (zh) * 2018-06-09 2019-12-12 江苏新元素医药科技有限公司 一类用于肝病治疗或预防的化合物
CN109432084A (zh) * 2018-12-26 2019-03-08 温州医科大学 一种抗癌组合物及其在药物制备中的应用
KR102682905B1 (ko) * 2020-10-22 2024-07-08 경희대학교 산학협력단 실리마린 매개된 셀레늄 나노입자 및 이의 용도
CN112494479B (zh) * 2020-12-28 2022-06-21 华中科技大学同济医学院附属同济医院 茶黄素在制备卵巢功能保护药物方面的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1215291B (it) * 1985-07-17 1990-01-31 Inverni Della Beffa Spa Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche.
GB2261434A (en) * 1991-11-15 1993-05-19 Inverni Della Beffa Spa New radical scavenging and antipoperoxidant flavanolignans their preparation and formulations for therapeutic use
CN1047944C (zh) * 1993-06-26 2000-01-05 曾庆通 一种治疗慢性肝炎的中药胶囊

Also Published As

Publication number Publication date
NO317153B1 (no) 2004-08-30
ATE268183T1 (de) 2004-06-15
KR100290030B1 (ko) 2001-05-15
US5912265A (en) 1999-06-15
CN1148181C (zh) 2004-05-05
NO975334L (no) 1997-11-20
DK0828500T3 (da) 2004-08-16
PT828500E (pt) 2004-08-31
KR19990014941A (ko) 1999-02-25
HK1006222A1 (en) 1999-02-19
DE69533112D1 (de) 2004-07-08
CA2221753A1 (en) 1996-11-28
SI0828500T1 (en) 2004-10-31
FI974268L (fi) 1997-12-02
CN1185112A (zh) 1998-06-17
WO1996037209A1 (en) 1996-11-28
JP3178844B2 (ja) 2001-06-25
FI974268A0 (fi) 1997-11-18
US6218369B1 (en) 2001-04-17
HU220627B1 (hu) 2002-03-28
AU709802B2 (en) 1999-09-09
JPH10511685A (ja) 1998-11-10
RU2161488C2 (ru) 2001-01-10
CA2221753C (en) 2001-07-24
FI119100B (fi) 2008-07-31
ITMI951047A0 (it) 1995-05-23
EP0828500A1 (en) 1998-03-18
ES2222466T3 (es) 2005-02-01
IT1274549B (it) 1997-07-17
ITMI951047A1 (it) 1996-11-23
AU3805195A (en) 1996-12-11
EP0828500B1 (en) 2004-06-02
DE69533112T2 (de) 2004-10-21
HUT77966A (hu) 1998-12-28
PL323450A1 (en) 1998-03-30
PL182064B1 (pl) 2001-10-31

Similar Documents

Publication Publication Date Title
NO975334D0 (no) Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE258444T1 (de) Therapeutische chemokine rezeptor antagonisten
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
MY127082A (en) Synergistic methods and compositions for treating cancer
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
MY124465A (en) Reduction of infarct volume using citicoline
WO2002064214A8 (en) Anti cancer combination of substituted pyrroles and paclitaxel
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
KR950013519A (ko) 골절 예방 및 치료용 약제
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
ATE274523T1 (de) Tetrapeptid, das prostatafunktionen reguliert sowie seine zusammensetzungen und verwendungen
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees